Erica Wohlhüter verfügt über Studienerfahrung in folgenden Indikationsbereichen:
Clinical Trials (since 1998)
Cardiovascular Double Blind Randomized Parallel Study to compare the influence of the angiotensin AT 1 antagonist losartan on the ultrasonographically determined intima media thickness of the carotid artery with that of the beta blocker atenolol in patients with mild to moderate essential hypertension (Phase II).
Open, Prospective and Randomized Study in Patients with Hypercholesterolemia and Hypertonia (Phase IV).
A Multicenter, Double - Blind, Randomized, Parallel, Captopril - Controlled Study to Evaluate the Effects of Losartan on Mortality in Patients with an Acute Myocardial infarction (Phase III) OPTIMAAL Merck.
Double Blind Randomized Parallel Study to compare the influence of the angiotensin AT 1 antagonist losartan on the ultrasonographically determined intima media thickness of the carotid artery with that of the beta blocker atenolol in patients with mild to moderate essential hypertension (Phase III) LARS Merck.
A prospective, randomised, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of tenecteplase during cardiopulmonary resuscitation as compared with standard treatment in patients suffering from out-of hospital cardiac arrest of presumed cardiac arrest (TROICA – Thrombolysis in Cardiac Arrest).
Randomized Evaluation of Long term anticoagulant therapy comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a prospective, multi-centre, parallel-group, non-inferiority trial (RELY). 44 Countries, 18113 Patients, 1000 Sites (Phase III).
Asthma A Randomized, Double - Blind, Multicenter Study to Evaluate the Effect of Oral Montelukast Sodium versus Fluticasone Propionate in Patients with Mild Persistent Asthma (Phase IV) Singulair 905 Merck.
COPD (chronic obstructive pulmonary disease) A Randomized, Double - Blind, Cross - over Study to Evaluate the FEV1 in Patients with chronic - obstructive - pulmonary - disease (Phase III).
Oncology A Multicenter, Double - Blind, Randomized, Comparative Study to evaluate the Safety, Tolerability and Efficacy of MK 991 Versus Amphotericin B Liposome for Infection as Empirical Therapy in Children with persistent Fever and Neutropenia (Phase III) MK 0 991 Wyeth.
Diabetes mellitus Randomised, double blind within dose group, multiple doses in patients with type II diabetes. Safety, tolerability, pharmacokinetics and pharmacodynamics of 4 weeks treatment with three oral doses of BI 10773 as tablets in male and female patients (Phase II).
Rheumatoid arthritis A Double - Blind, Randomized, Stratified, Parallel - Group Study to Asses the Incidence of PUBs during chronic treatment with MK - 966 or Naproxen in Patients with Rheumatoid Arthritis (Phase III) , international cohort; MK 0966 VIGOR Merck.
Degenerative Disc disease Medical Product: A Multicenter, Randomized Study to Evaluate the Tolerability and Efficacy of Prosthetic disc nucleus (Polymeric Hydrogel encased in a High-Tenacity Polyethylene Jacket) in Patients with degenerative disc disease (Phase II and III), Observational Trials.
Healthy Volunteers (Trial in England, Paris and Ireland) A Longitudinal Population – Based Study of Peripheral Blood Gene Expression Profiles in Healthy Volunteers; Peripheral blood Mononuclear cell (PMBC) messenger ribonucleic acid (mRNA) expression can be used to monitor gene expression changes in disease and in response to drug treatment.
Asthma bronchial (Trial in Ireland) A Prospective, No interentional, Exploratory, Gene Expression Study in Adults with Mild, Moderate and Severe Persistent Asthma 9998A1-900-WW Wyeth.